AstraZeneca ((AZN)), Bayer AG ((BAYRY)), AstraZeneca plc ((GB:AZN)), Bayer Ag (UK) ((GB:0P6S)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca and Bayer are collaborating on a clinical study titled A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA). The study aims to evaluate the safety and preliminary efficacy of AZD5305 combined with new hormonal agents in treating metastatic prostate cancer, a significant concern in oncology.
The study tests AZD5305, an experimental drug, in combination with four different hormonal agents: Enzalutamide, Abiraterone Acetate, Darolutamide, and Apalutamide. These combinations are intended to enhance treatment efficacy for metastatic prostate cancer patients.
This interventional study is non-randomized with a parallel assignment model and no masking. Its primary purpose is treatment, focusing on assessing the safety and efficacy of the drug combinations.
The study began on June 2, 2022, with an estimated primary completion date in 2025. The last update was submitted on July 14, 2025, indicating ongoing recruitment and data collection.
The collaboration between AstraZeneca and Bayer in this study could influence their stock performance positively if results show promising efficacy and safety. This could also impact investor sentiment favorably, especially in the competitive oncology market where advancements are closely watched.
The study is ongoing, and further details are available on the ClinicalTrials portal.